Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis

Autor: George A W Bruyn, R. N. J. de Nijs, Roland Laan, B A C Dijkmans, A. Algra, J. W. J. Bijlsma, A. M. Huisman, Erik Buskens, Piet Geusens, C.E.D. de Laet, J. W. G. Jacobs, Willem F. Lems, Ans C. M. Oostveen

Publikováno v: The New England Journal of Medicine, 355, 675-84
New England Journal of Medicine, 355(7), 675-684. MASSACHUSETTS MEDICAL SOC
University of Groningen
The New England Journal of Medicine, 355, 7, pp. 675-84

Bone loss and fracture are not infrequent when patients with rheumatic disorders are given glucocorticoid treatment. Glucocorticoids inhibit bone formation and also increase the rate of bone resorption. In addition, they decrease intestinal calcium a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bdfacba148f814d72e57801f9f17850
https://doi.org/10.1056/nejmoa053569

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.